Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

5 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

GECCO - German Corona Consensus - Covid-19 Research-Dataset - Symptome

- 05/01/23 - 13 moduli, 7 itemgroups, 80 elementi, 1 linguaggio
Itemgroups: Symptome, Atemwegssymptome, Systemische Symptome, Neurologische/Psychiatrische Symptome, Schmerzen, Magendarmsymptome, Andere Symptome
Disclaimer: Der „GECCO - German Corona Consensus - Covid-19 Research-Dataset“ Inhalt, der auf dem Portal für medizinische Datenmodelle (MDM Portal) zu finden ist, ersetzt nicht den GECCO Datensatz auf simplifier.net. Für die Nutzung von GECCO-FHIR-Profilen verwenden Sie bitte die auf https://simplifier.net/ForschungsnetzCovid-19/ verfügbaren Profile. Der FHIR-Download auf MDM erzeugt lediglich eine FHIR-Fragebogenresource. Ziel Überarbeitung August 2021: höhere Kompatibilität mit der NUM-COMPASS-App bzw. der Schnittstelle zur zentralen Datenbank; Zwischenstand, gewisse Module sind noch nicht kompatibel mit der Schnittstelle (u.a. Medikation und Laborwerte; Beatmungstherapie ist aktuell doppelt hinterlegt) This version of the GECCO logical model is based on https://art-decor.org/art-decor/decor-datasets--covid19f-, and the implementation for REDCap by the University of Tübingen (3.3.2021), partially updated with https://simplifier.net/guide/GermanCoronaConsensusDataSet-ImplementationGuide/Home information. For actual use of FHIR profiles, please use the actual profiles available on https://simplifier.net/ForschungsnetzCovid-19/ResearchDatasetGECCO/~overview (FHIR download on MDM is only a FHIR questionnaire resource). This version is not compatible with the REDCap to FHIR GECCO converter of the University of Tübingen. It aims at a higher compatibility with the app generated for the NUM-COMPASS project (conversion to COMPASS-compatible FHIR questionnaire necessary) and from there with the central platform of the NUM-CODEX project. A few modules are not yet compatible (e.g. Medication and lab values; ventilation is currently double). Official German text from http://cocos.team/datasets.html: Zur Bewältigung der aktuellen Pandemie und der damit einhergehenden Behandlung von Patienten fördert das Bundesministerium für Bildung und Forschung (BMBF) ein nationales Netzwerk der Universitätsmedizin im Kampf gegen COVID-19. Unter anderem soll das Netzwerk die Daten der behandelten COVID-19 Patienten systematisch erfassen und bündeln. Die Forschenden sollen die Behandlung der COVID-19-Patienten standardisiert erheben, verfolgen und analysieren. Die hohe Bedrohungslage hat zu intensiver wissenschaftlicher Aktivität zu COVID-19 geführt, wozu zahlreiche regionale, nationale und internationale epidemiologische Erhebungen und Registerstudien zählen. Der Konsensusdatensatz gibt der Wissenschaft um COVID-19 eine gemeinsame Sprache und Arbeitsgrundlage. Inofficial translation: In order to cope with the current pandemic and the associated treatment of patients, the Federal Ministry of Education and Research (BMBF) is funding a national network of university medicine in the fight against COVID-19. Among other things, the network will systematically collect and bundle the data of the treated COVID-19 patients. The researchers are to collect, track and analyze the treatment of COVID-19 patients in a standardized way. The high threat level has led to intensive scientific activity on COVID-19, including numerous regional, national and international epidemiological surveys and register studies. The consensus data set provides a common language and working basis for the science around COVID-19.

Studieneinschluss/Einschlusskriterien

1 ItemGroup 3 elementi

Vitalparameter

2 itemgroups 18 elementi

Therapie

1 ItemGroup 11 elementi

Laborwerte

26 itemgroups 78 elementi

Anamnese/Risikofaktoren

16 itemgroups 101 elementi

Medikation

5 itemgroups 56 elementi

ELaPro, a LOINC-Mapped Core Dataset for Top Laboratory Procedures of Eligibility Screening for Clinical Trials.

- 13/10/21 - 1 modulo, 1 ItemGroup, 55 elementi, 1 linguaggio
ItemGroup: Laboratory Tests
ELaPro (Eligibility Laboratory Procedures), a novel, LOINC-mapped, core dataset for the most frequent 55 laboratory procedures ordered in eligibility criteria to recruit patients for clinical trials. This core dataset is based on asemi-automated analysis of 10516 screening EC forms from MDM Portal in 2021.

Minimal data set for biomaterial, UMG Biobank - Minimal data set for biomaterial

- 30/10/19 - 1 modulo, 2 itemgroups, 15 elementi, 2 lingue
Itemgroups: Minimal dataset for biomaterial, Tumor entity
The usefulness of biomaterial depends to a large extent on the associated data. Therefore the UMG (Universitätsmedizin (University Medical Center) Göttingen) Biobank recommends to collect a minimum data set for each biomaterial. It should be noted that the available data set contains only minimal information. In addition, the collection of further data may be necessary, depending on the research purpose. Advice on the collection of data is expressly recommended. This document contains the minimum data set for the use of biomaterial. Note: The English Version is not an official translation. The original form language is German.

Missing Data GSK Ropinirole Restless Legs Syndrome 101468

- 18/09/17 - 1 modulo, 2 itemgroups, 6 elementi, 1 linguaggio
Itemgroups: Patient Information, Missing Data
Study ID: 101468/207 Clinical Study ID: SKF-101468/207 Study Title:A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Restless Legs Syndrome Missing Data

Visit 1 Run-In Date of Visit NCT01117584

- 28/01/17 - 1 modulo, 1 ItemGroup, 1 elemento, 1 linguaggio
ItemGroup: Date of Visit
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial